The members are: Mark S Bauer, Charles L. Bowden (with financial ties to Abbot, GSK, Janssen), Joseph Calabrese (Abbot, GSK, Janssen), Alan Gelenberg (GSK), Michael E. Thase (GSK, Janssen), Gary S Sachs (lead author of the study who sits on Advisory Board, Speakers Bureau and is consultant for or receives grants from Abbot, GSK, Janssen) and John M. Zajecka (Abbot, GSK).
Bauer, along with at least six other DBSA Advisory Board members-Charles L. Bowden (financial ties to Abbot, GSK, Janssen), Joseph Calabrese (Abbot, GSK, Janssen), Alan Gelenberg (GSK), Michael E. Thase (GSK, Janssen), Gary S Sachs (sits on Advisory Board, Speakers Bureau and is consultant for, Grants from Abbot, GSK, Janssen) and John M. Zajecka (Abbot, GSK) -conducted an $26.8 MILLION NIMH-FUNDED clinical study on the so-called Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) coordinated by Massachusetts General Hospital, to examine the course of the "disorder and the effectiveness of current treatments," including at least 7 drugs. Each of those involved in the NIMH-funded study had ties to drug companies (see above) that make the drugs studied.
MICHAEL E. THASE, MD, VICE CHAIR of the DBSA Committee: Professor of Psychiatry, University of Pittsburgh, School of Medicine and the Western Psychiatric Institute and Clinic.
Thase has directed the Depression Treatment and Research Program at Western Psychiatric Institute and Clinic since its inception in 1987 and is now the chief of adult academic psychiatry.
Member of the American College of Neuropsychopharmacology
Editor-in-chief of Psychopharmacology Bulletin.
Thase's Financial Disclosure
: Grant/Research Support: Bristol-Myers Squibb, Cyberonics, Merck, Organon, Pharmacia & Upjohn, Wyeth Ayerst Laboratories, Eli Lilly, and Sepracor
Consultant: AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Forest Pharmaceuticals, GSK, Glaxo-Wellcome Inc./CeNeRx Pharmaceuticals, Eli Lilly, Janssen, MedAvante, Inc, Merck, Neuronetics, Inc, Novartis, Organon, Ortho-McNeil-Janssen Pharmaceuticals, Pfizer, Pharmacia & Upjohn, Sepracor Inc, Shire, Supernus Pharmaceuticals, and Wyeth Ayerst
: AstraZeneca, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest, GSK, Glaxo-Wellcome Inc./CeNeRx Pharmaceuticals, Organon, Parke-Davis Pharmaceuticals, Pfizer, Pharmacia & Upjohn, Sanofi-Aventis, SmithKline Beecham, Solvay, and Wyeth Ayerst Laboratories, Inc.
Owns stock in MedAvante, Inc. (a company that provides services to improve methodology and objectivity in CNS clinical trials.) Receives book royalties from American Psychiatric Publishing
, Guilford Publications
, and Herald House.Many of the studies in which Thase has been involved are with Wyeth employees.
Executive Directors and directors of this includes DBSA members, David Dunner, Alan J. Gelenberg, Mark S. Bauer, Joseph Biederman, Joseph R. Calabrese, Pedro L. Delgado, Barbara Geller, Frederick K. Goodwin Robert M. A. Hirschfeld, Wayne J. Katon, Paul E. Keck Jr., Martin B. Keller, Lauren B. Marangell, Susan L. McElroy, David J. Miklowitz, Charles B. Nemeroff, Charles O'Brien, Robert M. Post, A. John Rush Jr., Gary S. Sachs, Alan F. Schatzberg, Trisha Suppes, Michael E. Thase, Karen D. Wagner, and John M. Zajecka.